Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs - PubMed (original) (raw)
Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs
I F McMurtry et al. Circ Res. 1976 Feb.
Abstract
The role of a transmembrane calcium influx in hypoxic pulmonary vasoconstriction was studied in isolated, blood-perfused, rat lungs. We reasoned that, if the influx of extracellular calcium mediated the hypoxic mechanism, pressor responses to alveolar hypoxia (2.5% O2) would be susceptible to inhibition by the calcium antagonists verapamil (2 X 10(-5) to 2 X 10(-1) mM) and SKF 525A (2.6 to 260 mM). Susceptibility of hypoxic pressor responses to inhibition by these calcium antagonists was contrasted to that of pressor responses elicited by the humoral vasoconstrictors angiotensin II(1 or 0.5 mug) and prostaglandin F2alpha (10 myg). Since neither saralasin (0.5 muM), a competitive antagonist of angiotensin II, nor meclofenamate (6.8 muM), an inhibitor of prostaglandin synthesis, depressed hypoxic pressor responses, it was concluded that these humoral transmitters were not directly involved in the hypoxic mechanism, and therefore served as independent reference agonists. The order of susceptibility of pulmonary pressor responses to inhibition by verapamil was hypoxia greater than angiotensin II greater than prostaglandin F2alpha. SKF 525A also reduced pressor responses to hypoxia more readily than those to angiotensin II. The greater inhibition of hypoxic pulmonary vasoconstriction by both calcium antagonists suggested that the hypoxic mechanism was critically dependent on the transmembrane influx of extracellular calcium. Mediation of the hypoxic response by this type of excitation-contraction coupling is consistent with the idea that hypoxia has a direct depolarizing effect on the vascular smooth muscle. It also provides a unifying explanation for inhibition of the hypoxic mechanism by various agents that have depressant or stabilizing actions on membranes in addition to other pharmacological effects.
Similar articles
- Inhibitors of oxidative ATP production cause transient vasoconstriction and block subsequent pressor responses in rat lungs.
Rounds S, McMurtry IF. Rounds S, et al. Circ Res. 1981 Mar;48(3):393-400. doi: 10.1161/01.res.48.3.393. Circ Res. 1981. PMID: 7460212 - Leukotriene synthesis and receptor blockers block hypoxic pulmonary vasoconstriction.
Morganroth ML, Reeves JT, Murphy RC, Voelkel NF. Morganroth ML, et al. J Appl Physiol Respir Environ Exerc Physiol. 1984 May;56(5):1340-6. doi: 10.1152/jappl.1984.56.5.1340. J Appl Physiol Respir Environ Exerc Physiol. 1984. PMID: 6373695 - Attenuation of hypoxic pulmonary vasoconstriction by verapamil in intact dogs.
Tucker A, McMurtry IF, Grover RF, Reeves JT. Tucker A, et al. Proc Soc Exp Biol Med. 1976 Mar;151(3):611-4. doi: 10.3181/00379727-151-39271. Proc Soc Exp Biol Med. 1976. PMID: 1257266 - Angiotensin, hypoxia, verapamil and pulmonary vessels.
Suggett AJ, Mohammed FH, Barer GR. Suggett AJ, et al. Clin Exp Pharmacol Physiol. 1980 May-Jun;7(3):263-74. doi: 10.1111/j.1440-1681.1980.tb00070.x. Clin Exp Pharmacol Physiol. 1980. PMID: 7398135 - Effects of ouabain, low K+, and aldosterone on hypoxic pressor reactivity of rat lungs.
Herget J, McMurtry IF. Herget J, et al. Am J Physiol. 1985 Jan;248(1 Pt 2):H55-60. doi: 10.1152/ajpheart.1985.248.1.H55. Am J Physiol. 1985. PMID: 3970175
Cited by
- Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.
Chang SW, Feddersen CO, Henson PM, Voelkel NF. Chang SW, et al. J Clin Invest. 1987 May;79(5):1498-509. doi: 10.1172/JCI112980. J Clin Invest. 1987. PMID: 3553241 Free PMC article. - Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?
Lambert M, Capuano V, Olschewski A, Sabourin J, Nagaraj C, Girerd B, Weatherald J, Humbert M, Antigny F. Lambert M, et al. Int J Mol Sci. 2018 Oct 14;19(10):3162. doi: 10.3390/ijms19103162. Int J Mol Sci. 2018. PMID: 30322215 Free PMC article. Review. - Detrimental effects of verapamil in patients with primary pulmonary hypertension.
Packer M, Medina N, Yushak M, Wiener I. Packer M, et al. Br Heart J. 1984 Jul;52(1):106-11. doi: 10.1136/hrt.52.1.106. Br Heart J. 1984. PMID: 6743418 Free PMC article. - AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling.
Zhao Q, Song P, Zou MH. Zhao Q, et al. Front Cell Dev Biol. 2021 Jun 8;9:691585. doi: 10.3389/fcell.2021.691585. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34169079 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources